Lantheus Holdings is one of the major radiopharmaceutical companies based in Massachusetts, USA, and specializes in radiodiagnostic medical imaging in urology, cardiology and neurology. The company’s flagship product, Pylarify, is
The U.S. Food and Drug Administration approved Rasonque (daraxonrasib) on Wednesday, August 26, 2026. The decision came 6.5 months in advance of the PDUFA date and marks a historic milestone
ITM Isotope Technologies Munich (ITM), announced on Nov. 13 that the U.S. FDA has accepted the company’s NDA for n.c.a. 177Lu-edotreotide (ITM-11, 177Lu-edotreotide), a targeted radiotherapeutic investigational agent for the treatment of
Coronary artery disease (CAD) is a leading cause of death worldwide, and requires precise, accessible, and versatile diagnostic imaging agents. Myocardial perfusion imaging (MPI) plays a central role in evaluating
Several leading companies in the nuclear medicine targeted imaging space have seen their stock valuations decline in recent quarter, despite continued clinical progress. Stock prices of companies like Lantheus Holdings,
On August 11, 2025, the Society of Nuclear Medicine and Molecular Imaging (SNMMI) introduced the “Global Radiopharmaceutical Clinical Trials Finder”, an AI-supported platform designed to make patient enrollment in nuclear
Targeted radiopharmaceutical therapies have emerged as an excellent treatment option for patients with inoperable metastatic neuroendocrine tumors (NETs). Currently approved therapies work by targeting somatostatin receptor expressed on NET cells.
On March 28, 2025, FDA approved the use of Pluvicto® before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer (mCRPC )patients who have previously been treated with androgen receptor pathway inhibitor
The global radiopharmaceutical market is a large and rapidly growing industry, driven by advancements in radiodiagnostics, radiotherapeutics and population demand. The advances in radiodiagnostics is helping detect diseases like cancer in
Lantheus Holdings is one of the major radiopharmaceutical companies based in Massachusetts, USA, and specializes in radiodiagnostic medical imaging in urology, cardiology and neurology. The company’s flagship product, Pylarify, is
The U.S. Food and Drug Administration approved Rasonque (daraxonrasib) on Wednesday, August 26, 2026. The decision came 6.5 months in advance of the PDUFA date and marks a historic milestone
ITM Isotope Technologies Munich (ITM), announced on Nov. 13 that the U.S. FDA has accepted the company’s NDA for n.c.a. 177Lu-edotreotide (ITM-11, 177Lu-edotreotide), a targeted radiotherapeutic investigational agent for the treatment of
Coronary artery disease (CAD) is a leading cause of death worldwide, and requires precise, accessible, and versatile diagnostic imaging agents. Myocardial perfusion imaging (MPI) plays a central role in evaluating
Several leading companies in the nuclear medicine targeted imaging space have seen their stock valuations decline in recent quarter, despite continued clinical progress. Stock prices of companies like Lantheus Holdings,
On August 11, 2025, the Society of Nuclear Medicine and Molecular Imaging (SNMMI) introduced the “Global Radiopharmaceutical Clinical Trials Finder”, an AI-supported platform designed to make patient enrollment in nuclear
Targeted radiopharmaceutical therapies have emerged as an excellent treatment option for patients with inoperable metastatic neuroendocrine tumors (NETs). Currently approved therapies work by targeting somatostatin receptor expressed on NET cells.
On March 28, 2025, FDA approved the use of Pluvicto® before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer (mCRPC )patients who have previously been treated with androgen receptor pathway inhibitor
The global radiopharmaceutical market is a large and rapidly growing industry, driven by advancements in radiodiagnostics, radiotherapeutics and population demand. The advances in radiodiagnostics is helping detect diseases like cancer in
“Supply Chain Logistics For A PET Radiotracer Manufacture”
Supply chain for an 18F radioisotope based PET radiotracer manufacture is discussed in detail along with brief manufacturing descriptions provided for context. A critical report for supply chain, manufacturing, business and investing personnel to familiarize with the basics of supply chain for this category of high application, commercially critical PET diagnostic imaging agents.
Click the icon below to download the eReport.
